Incidence and risk of advanced age-related macular degeneration in eyes with drusenoid pigment epithelial detachment

Shijo, Taiyo; Sakurada, Yoichi; Takada, Koji; Miki, Akiko; Sugiyama, Atsushi; Onoe, Hajime; Chubachi, Aya; Kikushima, Wataru; Wakatsuki, Yu; Yoneyama, Seigo; Mori, Ryusaburo; Kashiwagi, Kenji

doi:10.1038/s41598-022-08626-x

Cited by 8 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drusenoid PED pathogenesis and its implication in nAMD is still unknown but it is though that they are associated with an increased risk of advanced AMD with atrophy or brosis development (34). Thus, achieving a attening or reduction in a PED early in disease might be of bene t. Javaheri et al demonstrated that one-third of 586 eyes had a attened PED after an initial ranibizumab injection (35).…”

Section: Discussionmentioning

confidence: 99%

Faricimab in Neovascular AMD

Stanga

Bravo²,

Stanga³

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Assess short-term real-world outcomes in neovascular aged-related macular degeneration (nAMD) treated with novel faricimab. Methods Retrospective case series of nine patients with nAMD (11 eyes) treated with faricimab between May and November 2022. Treatment-naïve patients and non-naïve patients underwent best corrected visual acuity (BCVA), optical coherence tomography (OCT) DRI OCT-1 Triton (Topcon Corp, Tokyo, Japan), ultra-widefield (UWF) and fundus autofluorescence (FAF) (California Optomap, Optos plc, Dunfermline, Scotland, UK). Previous treatment intervals, number of intravitreal injections, sub/intra retinal fluid (SRF/IRF), central retinal thickness (CRT) and presence/changes in pigment epithelial detachments (PEDs) were recorded. Results Mean baseline BCVA and CRT values of patients who switched from other agents were 0.612 and 256.16 µm respectively, with a mean 36-day previous treatment interval. The median number of other previous anti-VEGF intravitreal injections was 8. The mean baseline BVCA and CRT values of the 3 naïve patients were 0.33 and 874.67 µm, respectively. At one month follow-up, mean BCVA improvement was 0.32 and mean CRT reduction was 338.44 µm. A complete resolution of SRF and IRF was observed in 75% and 33.33%, respectively. Drusenoid PED morphology changes were observed in all patients. No drug-related adverse events were observed. Conclusion Real-world outcomes showed improvement in BCVA and anatomic parameters at an early timepoint, demonstrating the efficacy and durability of faricimab in nAMD patients. Larger numbers of patients and longer follow-up are needed to determine whether the loading dose is required in all; what percentage of patients experience an improvement, and whether improvement it is maintained.

show abstract

Section: Discussionmentioning

confidence: 99%

Faricimab in Neovascular AMD

Stanga

Bravo²,

Stanga³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Shijo et al 18 studied the 5‐year cumulative incidence of advanced AMD in eyes with dPEDs, including GA and nAMD, being ~30%. A larger baseline dPED width was the only risk factor detected for advanced AMD.…”

Section: Biomarkersmentioning

confidence: 99%

“…Drusenoid pigment epithelial detachments (dPED) are characterised by the confluence of soft drusen, generally in the centre of the macula, containing a variable amount of serous and drusenoid material on OCT and with variable amount of pigmentary changes associated (Figure 2, panels A,B) [18][19][20] Cukras et al defined these lesions as 350 μm in diameter or greater. Shijo et al 18 studied the 5-year cumulative incidence of advanced AMD in eyes with dPEDs, including GA and nAMD, being 30%.…”

Section: Drusenoid Pigment Epithelial Detachmentmentioning

confidence: 99%

Section: Drusenoid Pigment Epithelial Detachmentmentioning

confidence: 99%

See 1 more Smart Citation

Optical coherence tomography biomarkers in early and intermediate age‐related macular degeneration: A clinical guide

Vidal‐Oliver,

Montolío‐Marzo,

Gallego‐Pinazo

et al. 2024

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Advanced forms of age‐related macular degeneration (AMD), characterised by atrophic and neovascular changes, are a leading cause of vision loss in the elderly population worldwide. Prior to the development of advanced AMD, a myriad of risk factors from the early and intermediate stages of AMD have been published in the scientific literature over the last years. The ability to precisely recognise structural and anatomical changes in the ageing macula, altogether with the understanding of the individual risk implications of each one of them is key for an accurate and personalised diagnostic assessment. The present review aims to summarise updated evidence of the relative risk conferred by diverse macular signs, commonly seen on optical coherence tomography, in terms of progression to geographic atrophy or macular neovascularization. This information may also serve as a basis for tailored follow‐up monitoring visits.

show abstract

“…Drusenoid PED was defined as an elevated mound with confluent soft drusen .500 mm on spectraldomain OCT (SD-OCT) as in previous investigations. 13,14 Only cases followed up for .24 months after the initial diagnosis were included for the analysis. If both eyes showed drusenoid PED, only the right eye was included.…”

Section: Study Populationmentioning

confidence: 99%

Subretinal Fluid Associated With Drusenoid Pigment Epithelial Detachment

Cho

Jeon

Yoon

et al. 2023

Retina

View full text Add to dashboard Cite

Purpose: To analyze the clinical characteristics of drusenoid pigment epithelial detachment (PED) with subretinal fluid (SRF) and to evaluate the impact of SRF on the long-term visual and anatomical outcomes. Methods: Forty-seven eyes with drusenoid PED (47 patients) who completed >24 months of follow-up were retrospectively analyzed. Intergroup comparisons of the visual and anatomical outcomes with and without SRF were made. Results: The mean duration of follow-up was 32.9 ± 18.7 months. The group with drusenoid PED with SRF (14 eyes) showed significantly higher PED height (468 ± 130 µm vs. 313 ± 88 µm, P < 0.001), larger PED diameter (2,328 ± 953 µm vs. 1,227 ± 882 µm, P < 0.001), and larger PED volume (1.88 ± 1.73 mm3 vs. 1.12 ± 1.35 mm3, P = 0.021) than that in the group with drusenoid PED without SRF (33 eyes) at baseline. No significant intergroup difference was found regarding the best-corrected visual acuity at the final visit. In addition, the incidence of complete retinal pigment epithelial and outer retinal atrophy (cRORA; 21.4%) and the development of macular neovascularization (MNV; 7.1%) for the group with drusenoid PED with SRF showed no difference compared with those (39.4% for cRORA development and 9.1% for MNV development) with drusenoid PED without SRF. Conclusion: The size, height, and volume of drusenoid PED were associated with the development of SRF. The SRF in drusenoid PED did not affect the visual prognosis or the development of macular atrophy during long-term follow-up.

show abstract

Incidence and risk of advanced age-related macular degeneration in eyes with drusenoid pigment epithelial detachment

Cited by 8 publications

References 24 publications

Faricimab in Neovascular AMD

Faricimab in Neovascular AMD

Optical coherence tomography biomarkers in early and intermediate age‐related macular degeneration: A clinical guide

Subretinal Fluid Associated With Drusenoid Pigment Epithelial Detachment

Contact Info

Product

Resources

About